Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Joseph E. Maakaron, Cassie Seichter, Rose Wangen, Andrea Hoeschen, Deepa Kolaseri Krishnadas, Kateryna Kent, Ryan Shanley, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeffrey S Miller

Blood (2023) 142 (Supplement 1): 4842.

https://doi.org/10.1182/blood-2023-189132

Published: 2023

Journal Articles

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada-Merly, Jaime M. Preussler, Tony Truong, Jesse Troy, Nandita Khera, William Wood, Hemalatha G. Rangarajan, Luke Akard, Neel S. Bhatt, Akshay Sharma, Wael Saber

Blood (2023) 142 (Supplement 1): 373.

https://doi.org/10.1182/blood-2023-182013

Published: 2023

Journal Articles

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Shernan G. Holtan, Kelly Walton, Najla H El Jurdi, Joseph E. Maakaron, Mark Juckett, Veronika Bachanova, Thomas Myers, Linda J. Paradiso, Todd DeFor, Qing Cao, Brian Betts

Blood (2023) 142 (Supplement 1): 4925.

https://doi.org/10.1182/blood-2023-181292

Published: 2023

Journal Articles

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

Nuttavut Sumransub, Cassie Seichter, Kateryna Kent, Ryan Shanley, Marie Hu, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeremy R. Allred, Veronika Bachanova, Jeffrey S Miller, Joseph E. Maakaron

Blood (2023) 142 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2023-187070

Published: 2023

Journal Articles

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Peter Westervelt, Partow Kebriaei, Mark Juckett, Andrew S. Artz, Onyee Chan, Philip L. McCarthy, Sherif S Farag, Anurag K. Singh, Eytan Stein, Jeffrey Humphrey, William Baeder, Ji Hyun Lee, Alison Occhiuti, Jeanie Tang, David Santos, Kirk Bertelsen, Balaji Mahender, Nicole Henry, Shawn Rose

Blood (2022) 140 (Supplement 1): 2117–2119.

https://doi.org/10.1182/blood-2022-162406

Published: 2022

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij

Blood (2022) 140 (Supplement 1): 10327–10328.

https://doi.org/10.1182/blood-2022-166728

Published: 2022

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Joseph Maakaron, Emily Stene, Megan Bruns, Todd E. DeFor, Najla H El Jurdi, Veronika Bachanova, Daniel J. Weisdorf, Jeffrey S. Miller, Murali Janakiram, Mark Juckett

Blood (2021) 138 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2021-149607

Published: 2021

Journal Articles

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

Muhammad Umair Mushtaq, MD, Sibgha Gull Chaudhary, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Sameem Abedin, MD, Lyndsey Runass, MD, Michael J. Fallon, PharmD, Alexandra M. Harrington, MD, Mark Juckett, MD, Aric C. Hall, MD, Ryan J. Mattison, MD, Ehab L. Atallah, MD, Guru Subramanian Guru Murthy, MBBS

Blood (2018) 132 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2018-99-113764

Published: 2018

Journal Articles

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Christopher R. D'Angelo, MD, Aric C. Hall, MD, Kyungmann Kim, PhD, Ryan J. Mattison, MD, Walter L. Longo, MD, Peiman Hematti, MD, Natalie Scott Callander, MD, Mark Juckett, MD

Blood (2018) 132 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2018-99-112670

Published: 2018

Journal Articles

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Lyndsey Runaas, MD, Walter L. Longo, MD, Mark Juckett, MD, Wayne Borcherding, BS, Peiman Hematti, MD, Rachel J Cook, MD, MS

Blood (2013) 122 (21): 5490.

https://doi.org/10.1182/blood.V122.21.5490.5490

Published: 2013

Journal Articles

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Zhuoxin Sun, PhD, Peter L. Greenberg, MD, Mark Juckett, MD, Lisa Malick, Mitchell R Smith, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD

Blood (2010) 116 (21): 601.

https://doi.org/10.1182/blood.V116.21.601.601

Published: 2010

Journal Articles

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Willis H. Navarro, MD, Manza-A Agovi, MPH, Brent Logan, PhD, Andrea Bacigalupo, MD, Karen K Ballen, MD, Brian J. Bolwell, MD, Haydar Frangoul, MD, Vikas Gupta, MD, MRCP, MRCPath, Theresa Hahn, PhD, Mark Juckett, MD, Hillard M. Lazarus, MD, Mark R. Litzow, MD, Jane Liesveld, MD, Jan Moreb, MD, David Marks, MD, PhD, Philip L. McCarthy, MD, J. Douglas Rizzo, MD, MS

Blood (2008) 112 (11): 51.

https://doi.org/10.1182/blood.V112.11.51.51

Published: 2008

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

NARROW

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only